Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companyâs lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy. Source
No articles found.
We are developing nalbuphine ER to treat serious neurologically mediated condition...
We are developing nalbuphine ER to treat seriou...
CUTERA, Inc. was founded in 1998 and is a global provider of Face + Body laser, li...
CUTERA, Inc. was founded in 1998 and is a globa...
At Insmed we are on a mission to transform the lives of patients battling serious ...
At Insmed we are on a mission to transform the ...
IVERIC bio is a gene therapy focused company developing innovative treatments for ...
IVERIC bio is a gene therapy focused company de...
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developi...
Urovant Sciences is a clinical-stage biopharmac...
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
Join the National Investor Network and get the latest information with your interests in mind.